Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that the Company has recently received five awards recognizing its corporate accomplishments and digital marketing efforts, including the prestigious PM360 Trailblazer Award for Company of the Year in the category of Best Specialty Pharma/Biotechnology Company.
The Trailblazer Awards highlight outstanding achievement and innovation in healthcare marketing. In particular, Acorda was recognized for its pursuit of excellence in three separate areas: marketing and advertising, talent development and social responsibility. The award is presented by the widely-read PM360 magazine, a resource for marketing decision-makers in the pharmaceutical, biotech, and medical device industries. Award decisions are made by the PM360 Editorial Advisory Board, composed of distinguished healthcare marketing and other industry experts.
“We have more than 400 associates at Acorda who share the purpose of improving the lives of people with neurological diseases,” said Ron Cohen, M.D., Acorda's President and CEO. “This is a challenging goal that can only be achieved through commitment, perseverance and collaboration. It’s a privilege for all of us at Acorda to be recognized by PM360 for the contributions we are making to advance the care of people with these devastating illnesses.”
Acorda also was honored with three industry awards by three other prestigious organizations.The American Business Association recognized the Company’s corporate web site, www.acorda.com , with its 2013 Gold Stevie Award in the category of pharmaceutical website. The Web Marketing Association selected both the consumer and healthcare professional sections of Acorda’s product website, www.ampyra.com , as winners of the 2013 Pharmaceuticals Standard of Excellence Award. The Web Marketing Association’s WebAward program is the longest running annual website award competition. Medical Marketing & Media recognized ampyra.com with a Silver MM&M Award in the category of best branded website for consumers. This year's judging process included two comprehensive rounds of scoring by more than 100 independent judges who are seasoned industry professionals. Dr. Cohen said, “Bringing innovative medications to market is just one element of our mission to improve patient lives. We also seek to provide a broad range of important health information to patients, healthcare professionals and patient advocacy communities, and our online initiatives are key elements of these programs. Being acknowledged by our peers for the caliber of these initiatives is both satisfying and hugely motivating.”
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV